ANN ARBOR, Mich., – May 17, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces the first sample shipment of its recombinant spider silk fibers and fabrics for use and evaluation into a range of biomedical applications. This shipment was made in response to the significant increase in the requests for its propriety spider silk technology, over the last two quarters, for tissue engineering applications.
Aided by its unique blend of mechanical and chemical properties, spider silk has long been recognized as an ideal natural biomaterial. As a lightweight, biocompatible, and biodegradable material, spider silk applications have been tested in numerous morphologies, including; fibers, films, hydrogels, non-woven fabrics, foams, etc. While the first known cases of sutures made from spider silk date back to the 18th century, limitations in the production and costs of spider silk have prevented its broad adoption.
Kraig Labs’ revolutionary approach, creating recombinant spider silk technology utilizing genetically enhanced silkworms, unlocks the door for large-scale adoption of spider silk for biomedical applications. This system merges the performance of spider silk with the well-established, large-scale supply chain for mundane silk.
With the growth of its production operations in Vietnam over the last two quarters, the Company is now positioned to allot a portion of its spider silk production to address the medical community’s needs. This week’s shipments are just the first in what the Company hopes will be a significant mid to long-term market growth opportunity for Kraig Labs and its foray into the growing field of bioengineering.
“Over the last month, we have seen a significant increase in the demand from the medical field for our spider silk fibers and fabrics,” said COO, Jon Rice. “With the great work our team in Vietnam has done, increasing monthly silk production, we are now positioned to begin supplying R&D samples for this new and exciting end market. As these applications often require FDA approval, we believe the biomedical space has the potential to play an important role in the Company’s long-term growth. Over the coming months, we will be closely monitoring the results of these first tests and assessing additional opportunities for the spider silk gels and films that we have already developed into the broad field of biomaterials.”
Press release taken from: https://www.kraiglabs.com/kraig-biocraft-laboratories-enters-biomedical-field-with-first-sample-shipments-of-fibers-and-fabrics-for-tissue-engineering/
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
IMPORTANT PUBLISHER NOTICE AND DISCLOSURE: The featured company (the “Company”) profile in our featured magazine is paid advertising and does not purport to provide an analysis of the Company’s financial position, operations, or prospects. PUBLISHER or its affiliates have received shares as compensation, and will sell their shares anytime of their choosing, often to cover expenses related to the marketing of the magazine to interested readers. The 24/7 Market News editor and 24/7 Market News Inc. has been contracted by the Company’s IR rep KMK, for purchasing digital media for this publication. The editor also owns three million shares of stock which will be sold over the coming months as market conditions and news allow. Company expenses related to media purchases (up to twenty-five thousand dollars per month) will be spent on an ongoing basis, this payment and trading in the stock should be viewed as biased and a conflict of interest. PUBLISHER bases its profiles on the Company’s business plans, projections and public corporate information and there is no guarantee the Company will reach its projections. Companies traded on the Over-the-Counter Market are considered extremely high-risk investments and you should not invest in any Over-the-Counter company UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. PUBLISHER makes no warranties as to the accuracy of any of the content contained herein and accepts no liability for how readers may choose to utilize the content. Readers should perform their own due diligence, including reviewing the Company’s filings at www.sec.gov and consult with a licensed, qualified investment professional or analyst. The information contained herein contains forward-looking information within the meaning of Section 27a of the Securities act of 1993, as amended, and Section 21e of the Securities Exchange act of 1934, as amended, including statements regarding expected growth of the featured company. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act, PUBLISHER notes that statements contained herein that look forward in time, which include everything other than historical information; involve risks and uncertainties that may affect the Company’s actual results of operations. Factors that would cause actual results to differ include the size and growth of the market, the Company’s ability to fund its capital requirements in the near term and long term; pricing pressures, and market conditions. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals assumptions or future events or performance are forward-looking. The words or phrases “would be,” “will allow,” “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” “anticipate”, or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We caution readers not to place undue reliance on any forward-looking statements, which speak only as of the date made, are based on certain assumptions and expectations which may or may not be valid or actually occur, and which involve various risks and uncertainties. This report was written in reliance upon Information provided by the featured company. Although the PUBLISHER believes the information to be reliable, there is no guarantee of accuracy or completeness. The PUBLISHER has selected the information contained in the newsletter to present the Company in a favorable light. While the PUBLISHER has featured many winners over the years it has also featured companies that have lost value. This is a high risk high reward market. Accordingly, the PUBLISHER does not represent that this newsletter contains all of the material information required for an informed investment decision or that material facts have not been omitted. At any time if you are interested in an investment in one of the featured companies, the PUBLISHER recommends that you make independent verification of the information by contacting the Company. The PUBLISHER is engaged in the business of publishing Magazines about various small, developing companies seeking market recognition, usually as a step in obtaining needed financing. The PUBLISHER has criteria for selecting the companies for which it provides its services. However, the PUBLISHER does not perform an independent investigation to verify facts, as we are not a private investigation firm; we rely on the public statements made by the featured companies. While the PUBLISHER is looking for companies that have reliable public information, it is not a guarantee that it will be able to avoid scams or frauds. It relies on the companies’ officers, directors and counsel to be honest. Accordingly, the publication of a Magazine is not intended to imply that the PUBLISHER has selected any company for which it publishes a newsletter as having superior qualifications, better prospects, stronger management, greater financial strength, or other basis for being selected, rather the selected company exhibits qualities that the PUBLISHER believes are compelling.